Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Unusual Scenario: Ipsilateral Pelvic Lymph Node Metastasis in High- Grade Serous Ovarian Carcinoma without Peritoneal Extension - A Case Report

Author(s): Naina Kumar*, Ashutosh Rath, Mishu Mangla and Subhrajyoti Roy

Volume 20, Issue 5, 2024

Published on: 24 October, 2023

Page: [510 - 516] Pages: 7

DOI: 10.2174/0115733947267105231009061118

Price: $65

Abstract

Introduction: Ovarian cancers are the third most common gynecological cancers worldwide with serous carcinomas being the most common subtype with 90% of them as high-grade carcinomas.

Case Presentation: In the present case report a 60 years postmenopausal, nulliparous woman presented with complaints of bleeding per vaginum for 1-2 months with a left-sided solid-cystic ovarian mass of size 4x5 cm and ipsilateral enlarged external iliac and obturator lymph nodes which were diagnosed on histopathological examination as high-grade serous ovarian carcinoma (HGSOCs) with ipsilateral pelvic lymph node metastasis in presence of intact ovarian capsule and no metastatic deposits over the uterus, contralateral ovary and fallopian tubes, omentum, or any other gross peritoneal deposits. There was coexisting non-atypical endometrial hyperplasia. The patient was managed successfully with staging laparotomy with modified radical hysterectomy, and bilateral pelvic lymphadenectomy followed by six cycles of adjuvant chemotherapy with Paclitaxel and Carboplatin injections.

Conclusion: Patients with HGSOCs can have varied presentations with unusual involvement of lymph nodes in the absence of peritoneal spread. Hence, the clinician must be aware of these unusual presentations for the successful management of such cases.

« Previous Next »
Graphical Abstract

[1]
Huang, J.; Chan, W.C.; Ngai, C.H. Worldwide burden, risk factors, and temporal trends of ovarian Cancer: A global study. Cancers , 2022, 14(9), 2230.
[http://dx.doi.org/10.3390/cancers14092230] [PMID: 35565359]
[2]
PDQ Adult Treatment Editorial Board Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®): Health Professional Version 2023 Mar 14. PDQ Cancer Information Summaries. Bethesda (MD). In: National Cancer Institute (US); , 2002.
[3]
Momenimovahed, Z.; Tiznobaik, A.; Taheri, S.; Salehiniya, H. Ovarian cancer in the world: Epidemiology and risk factors. Int. J. Womens Health, 2019, 11, 287-299.
[http://dx.doi.org/10.2147/IJWH.S197604] [PMID: 31118829]
[4]
Shabir, S.; Gill, P.K. Global scenario on ovarian cancer – Its dynamics, relative survival, treatment, and epidemiology. Adesh Univ J Med Sci Res, 2020, 2(1), 17-25.
[http://dx.doi.org/10.25259/AUJMSR_16_2019]
[5]
Arora, T.; Mullangi, S.; Lekkala, M.R. Ovarian Cancer.In: StatPearls; StatPearls Publishing: Treasure Island, FL, 2023. Internet
[6]
Rosen, DG; Yang, G; Liu, G Ovarian cancer: Pathology, biology, and disease models. Front Biosci, 2009, Volume 14(2089), 102.
[http://dx.doi.org/10.2741/3364] [PMID: 19273186]
[7]
Stewart, C.; Ralyea, C.; Lockwood, S. Ovarian cancer: An integrated review. Semin. Oncol. Nurs., 2019, 35(2), 151-156.
[http://dx.doi.org/10.1016/j.soncn.2019.02.001] [PMID: 30867104]
[8]
Lisio, M.A.; Fu, L.; Goyeneche, A.; Gao, Z.; Telleria, C. High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int. J. Mol. Sci., 2019, 20(4), 952.
[http://dx.doi.org/10.3390/ijms20040952] [PMID: 30813239]
[9]
Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol., 2010, 177(3), 1053-1064.
[http://dx.doi.org/10.2353/ajpath.2010.100105] [PMID: 20651229]
[10]
Restaino, S.; Mauro, J.; Zermano, S. CUP-syndrome: Inguinal high grade serous ovarian carcinoma lymph node metastases with unknown primary origin – a case report and literature review. Front. Oncol., 2022, 12, 987169.
[http://dx.doi.org/10.3389/fonc.2022.987169] [PMID: 36300091]
[11]
Dam, K.; Peeters, F.; Verhoeven, D.; Duwel, V. High-grade serous cancer of undetermined primary origin presenting as solitary inguinal lymph node enlargement. BMJ Case Rep., 2021, 14(4), e239185.
[http://dx.doi.org/10.1136/bcr-2020-239185] [PMID: 33910789]
[12]
Zuhdy, M.; Alghandour, R.; Abdelazeem, G. Axillary nodal metastasis in ovarian cancer: A report of three cases and review of literature. J. Egypt. Natl. Canc. Inst., 2019, 31(1), 9.
[http://dx.doi.org/10.1186/s43046-019-0008-x] [PMID: 32372131]
[13]
Thomakos, N.; Diakosavvas, M.; Machairiotis, N.; Fasoulakis, Z.; Zarogoulidis, P.; Rodolakis, A. Rare distant metastatic disease of ovarian and peritoneal carcinomatosis: A review of the literature. Cancers , 2019, 11(8), 1044.
[http://dx.doi.org/10.3390/cancers11081044] [PMID: 31344859]
[14]
Purcell, C.; Al Afif, A.; Bullock, M.; Corsten, M. Ovarian cancer metastasis to the larynx: A case report and review of the literature. Case Rep. Surg., 2020, 2020, 1-4.
[http://dx.doi.org/10.1155/2020/1543129] [PMID: 32832186]
[15]
McMillen, B.D.; Aponte, M.M.; Liu, Z. Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma. Mod. Pathol., 2012, 25(12), 1644-1653.
[http://dx.doi.org/10.1038/modpathol.2012.118] [PMID: 22790015]
[16]
Yang, X.J.; Zheng, F.Y.; Xu, Y.S.; Ou, R.Y. Ovarian cancer initially presenting with isolated ipsilateral superficial inguinal lymph node metastasis: A case study and review of the literature. J. Ovarian Res., 2014, 7(1), 20.
[http://dx.doi.org/10.1186/1757-2215-7-20] [PMID: 24506831]
[17]
Dowson, C.B.; Stewart, C.; O’Sullivan, S.; Pachter, N.; Schofield, L.; Cohen, P.A. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas. Int. J. Gynecol. Cancer, 2020, 30(1), 94-99.
[http://dx.doi.org/10.1136/ijgc-2019-000540] [PMID: 31699802]
[18]
King, E.R.; Tung, C.S.; Tsang, Y.T.M. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am. J. Surg. Pathol., 2011, 35(6), 904-912.
[http://dx.doi.org/10.1097/PAS.0b013e318212ae22 ] [PMID: 21451362]
[19]
Saad, A.F.; Hu, W.; Sood, A.K. Microenvironment and pathogenesis of epithelial ovarian cancer. Horm. Cancer, 2010, 1(6), 277-290.
[http://dx.doi.org/10.1007/s12672-010-0054-2] [PMID: 21761359]
[20]
Skagias, L.; Ntinis, A.; Vasou, O.; Kondi-Pafiti, A.; Politi, E. Ovarian carcinoma presenting with axillary lymph node metastasis: A case diagnosed by fine-needle aspiration and brief review of the literature. Diagn. Cytopathol., 2008, 36(12), 891-893.
[http://dx.doi.org/10.1002/dc.20945] [PMID: 18925569]
[21]
Berek, J.S.; Renz, M.; Kehoe, S.; Kumar, L.; Friedlander, M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int. J. Gynaecol. Obstet., 2021, 155(S1), 61-85.
[http://dx.doi.org/10.1002/ijgo.13878] [PMID: 34669199]
[22]
Matsuo, K.; Sheridan, T.B.; Mabuchi, S. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol. Oncol., 2014, 133(3), 473-479.
[http://dx.doi.org/10.1016/j.ygyno.2014.03.563] [PMID: 24674832]
[23]
Matsuo, K.; Todd, S.; Yoshino, K. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol. Oncol., 2013, 130(1), e112.
[http://dx.doi.org/10.1016/j.ygyno.2013.04.324] [PMID: 24674832]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy